Latest Insider Transactions at Natus Medical Inc (NTUS)
This section provides a real-time view of insider transactions for Natus Medical Inc (NTUS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NATUS MEDICAL INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NATUS MEDICAL INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 21
2022
|
Alice D. Schroeder Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
22,406
-100.0%
|
$739,398
$33.5 P/Share
|
|
Jul 21
2022
|
Thomas Joseph Sullivan President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
720,903
-100.0%
|
$23,789,799
$33.5 P/Share
|
|
Jul 21
2022
|
Thomas Joseph Sullivan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
648,554
+47.36%
|
-
|
|
Jul 21
2022
|
Austin Francis Noll Iii Executive VP and CCO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
200,509
-100.0%
|
$6,616,797
$33.5 P/Share
|
|
Jul 21
2022
|
Austin Francis Noll Iii Executive VP and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
61,966
+23.61%
|
-
|
|
Jul 21
2022
|
Bryant M Moore Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,114
-100.0%
|
$333,762
$33.5 P/Share
|
|
Jul 21
2022
|
Joshua Levine Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
37,387
-100.0%
|
$1,233,771
$33.5 P/Share
|
|
Jul 21
2022
|
Lisa Wipperman Heine Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
26,287
-100.0%
|
$867,471
$33.5 P/Share
|
|
Jul 21
2022
|
Eric Guerin Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,114
-100.0%
|
$333,762
$33.5 P/Share
|
|
Jul 21
2022
|
Benjamin Drew Davies Executive VP and CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
181,846
-100.0%
|
$6,000,918
$33.5 P/Share
|
|
Jul 21
2022
|
Benjamin Drew Davies Executive VP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
106,034
+36.83%
|
-
|
|
Jul 21
2022
|
Ilan Daskal Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
18,937
-100.0%
|
$624,921
$33.5 P/Share
|
|
Jul 21
2022
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
83,374
-100.0%
|
$2,751,342
$33.5 P/Share
|
|
Jul 21
2022
|
Dong Chune Christopher Chung Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,056
+29.6%
|
-
|
|
Jun 15
2022
|
Ilan Daskal Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,075
+21.14%
|
-
|
|
Jun 15
2022
|
Eric Guerin Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,315
+29.91%
|
-
|
|
Jun 15
2022
|
Lisa Wipperman Heine Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,075
+16.18%
|
-
|
|
Jun 15
2022
|
Joshua Levine Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,075
+11.95%
|
-
|
|
Jun 15
2022
|
Bryant M Moore Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,315
+29.91%
|
-
|
|
Jun 15
2022
|
Alice D. Schroeder Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,075
+18.47%
|
-
|
|
Jan 04
2022
|
Benjamin Drew Davies Executive VP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,251
-1.62%
|
$30,024
$24.02 P/Share
|
|
Jan 04
2022
|
Austin Francis Noll Iii Executive VP and CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,710
-2.57%
|
$89,040
$24.02 P/Share
|
|
Jan 04
2022
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,796
-5.47%
|
$67,104
$24.02 P/Share
|
|
Jan 03
2022
|
Thomas Joseph Sullivan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
52,084
+41.86%
|
$1,250,016
$24.0 P/Share
|
|
Jan 03
2022
|
Dong Chune Christopher Chung Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,084
+21.6%
|
$338,016
$24.0 P/Share
|
|
Jan 03
2022
|
Austin Francis Noll Iii Executive VP and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
25,625
+15.08%
|
$615,000
$24.0 P/Share
|
|
Jan 03
2022
|
Benjamin Drew Davies Executive VP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
19,334
+20.06%
|
$464,016
$24.0 P/Share
|
|
Jan 02
2022
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,046
-9.85%
|
$93,058
$23.73 P/Share
|
|
Jan 02
2022
|
Austin Francis Noll Iii Executive VP and CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,904
-3.97%
|
$112,792
$23.73 P/Share
|
|
Jan 02
2022
|
Benjamin Drew Davies Executive VP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,621
-5.9%
|
$83,283
$23.73 P/Share
|
|
Dec 31
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,213
-2.87%
|
$27,899
$23.73 P/Share
|
|
Dec 31
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,363
+5.29%
|
$54,349
$23.73 P/Share
|
|
Dec 31
2021
|
Austin Francis Noll Iii Executive VP and CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,602
-1.28%
|
$36,846
$23.73 P/Share
|
|
Dec 31
2021
|
Austin Francis Noll Iii Executive VP and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
3,676
+2.85%
|
$84,548
$23.73 P/Share
|
|
Dec 31
2021
|
Benjamin Drew Davies Executive VP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,486
-3.89%
|
$57,178
$23.73 P/Share
|
|
Dec 31
2021
|
Benjamin Drew Davies Executive VP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
5,252
+7.6%
|
$120,796
$23.73 P/Share
|
|
Dec 09
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,787
-22.79%
|
$271,101
$23.08 P/Share
|
|
Dec 09
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,787
+18.56%
|
$235,740
$20.68 P/Share
|
|
Oct 01
2021
|
Benjamin Drew Davies Executive VP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,664
-4.35%
|
$66,600
$25.86 P/Share
|
|
Aug 18
2021
|
Bryant M Moore Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,799
+50.0%
|
$144,975
$25.87 P/Share
|
|
Aug 18
2021
|
Eric Guerin Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,799
+50.0%
|
$144,975
$25.87 P/Share
|
|
Jun 17
2021
|
Ilan Daskal Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,214
+27.33%
|
$145,992
$28.77 P/Share
|
|
Jun 17
2021
|
Alice D. Schroeder Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,214
+23.13%
|
$145,992
$28.77 P/Share
|
|
Jun 17
2021
|
Lisa Wipperman Heine Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,214
+19.73%
|
$145,992
$28.77 P/Share
|
|
Jun 17
2021
|
Joshua Levine Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,214
+13.89%
|
$145,992
$28.77 P/Share
|
|
Jun 17
2021
|
Barbara R Paul Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,214
+14.9%
|
$145,992
$28.77 P/Share
|
|
Jun 17
2021
|
Thomas Joseph Sullivan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
5,214
+20.46%
|
$145,992
$28.77 P/Share
|
|
Jun 11
2021
|
Ilan Daskal Director |
SELL
Open market or private sale
|
Direct |
2,500
-22.43%
|
$67,500
$27.46 P/Share
|
|
Jun 11
2021
|
Alice D. Schroeder Director |
SELL
Open market or private sale
|
Direct |
2,934
-19.49%
|
$79,218
$27.49 P/Share
|
|
Jun 01
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,500
-23.84%
|
$337,500
$27.55 P/Share
|